Keytruda is actually a brand (trade) name for pembrolizumab. It is given by intravenous infusion every three to six weeks. Seldom, the usage of Keytruda results from the immune system attacking balanced tissues which can cause major side effects like pneumonitis, colitis, or hepatitis. In lots of people, using Keytruda has resulted in the remission